Scientific Advisors

Jeffrey S. Miller, M.D.

Jeffrey S. Miller, M.D.

Consulting Chief Scientific Officer

Jeffrey S. Miller, MD, received a Bachelor of Science degree from Northwestern University in Evanston, Illinois and received his MD from Northwestern University School of Medicine. He completed an internship and residency in Internal Medicine at the University of Iowa in Iowa City. After completing a post-doctoral fellowship in Hematology, Oncology and Transplantation at the University of Minnesota, he joined the faculty in 1991. Dr. Miller is currently a Professor of Medicine at the University of Minnesota. He is the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. He has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. He is a member of numerous societies such as the American Society of Hematology, the American Association of Immunologists, a member of the American Society of Clinical Investigation since 1999. He serves on the editorial board for Blood and is a reviewer for a number of journals and NIH grants.

Dr. Arjun V Balar, MD

Dr. Arjun V Balar, MD, is an Associate Professor of Medicine at the NYU Grossman School of Medicine in New York, New York. He is the Director of the Genitourinary Medical Oncology Program and the Medical Director for the Clinical Trials Office at the NYU Langone Perlmutter Cancer Center. He primarily focuses on treating and managing genitourinary cancers, such as prostate cancer, bladder cancer, kidney cancer and testicular cancer. He has pioneered the development of immunotherapies for bladder cancer and metastatic urothelial carcinoma and is an internationally recognized leader in bladder cancer clinical trials. His research concentration includes molecularly targeted therapy as well as immunotherapy. Dr. Balar leads the NYU genitourinary tumor registry which is a multidisciplinary effort involing clinical, basic science and translational researchers to characterize the genomic and molecular make up of genitourinary tumors and to better understand its impact on patient outcomes. He is the editor of the periodical Targeted Therapeutics in Oncology. Dr. Balar completed residency at New York Presbyterian Weill Cornell Medical Center and is fellowship trained in oncology from Memorial Sloan Kettering Cancer Center.

Lisa A. Haile, Ph.D.

Dr. Lisa A. Haile, Ph.D. currently serves as Co-Chair, Global Life Sciences Sector at DLA Piper. Dr. Haile has special technical expertise in molecular biology and immunology . She has particular experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management and value creation. Dr. Haile is a member of DLA Piper's Executive Committee.

Dr. Haile's experience includes US and international patent preparation and prosecution as well as IP reviews for investors relating to technologies including novel genetically altered organisms, antisense, RNA and siRNA molecules, peptides, proteins, DNA, antibodies, vaccines, diagnostics and therapeutics. 

Dr. William Murphy, Ph.D.

Dr. Murphy spent his postdoctoral years and early career at the National Cancer Institute (NCI) in Frederick, Maryland. After 12 years, and becoming Director of Basic Research at NCI-Frederick in Maryland, he joined the faculty at the University of Nevada, Reno (UNR). Dr. Murphy later became the Chair of Microbiology and Immunology at UNR, School of Medicine. In 2008, Dr. Murphy moved his laboratory to UC Davis, accepting a position as Professor and Vice Chair of Research in the Department of Dermatology and Internal Medicine, Division of Hematology Oncology.

Dr. Murphy’s laboratory studies various aspects within cancer immunology and immunotherapy for melanoma. Current projects within the lab are exploring how to increase the success of these engraftments as well as to make them safer for patients by decreasing the period in which the patient is immune-compromised. Another focus within Dr. Murphy’s laboratory is studying how the immune system becomes activated after the systemic administration of immunotherapies. His laboratory has several NIH R01 grants and is also funded by CIRM looking at stem cell engraftment.

Dr. Murphy has over 200 publications in cancer immunology over his 25-year career and is active on multiple NIH Study Sections.

Dr. Samir Taneja, M.D.

Dr. Samir Taneja, M.D. is the James M. and Janet Riha Neissa Professor of Urologic Oncology and a Professor of Urology, Radiology and Biomedical Engineering at the New York University Grossman School of Medicine. Dr. Taneja additionally serves as Vice Chair of Urology and Director of the Division of Urologic Oncology in the School of Medicine, Director of the GU Oncology Program of the Perlmutter Cancer Center, and Co-Director of the Smilow Comprehensive Prostate Cancer Center at NYU Langone Health. Dr. Taneja received his medical degree from Northwestern University Medical School, and completed his surgical and urologic training at the University of California at Los Angeles. Dr. Taneja is a leader in the diagnosis, treatment and research of urologic cancers having published numerous articles, chapters, and edited textbooks in the field.

Daniel Vallera, Ph.D.

Dr. Vallera received his Ph.D. in Microbiology (Immunology) from the Ohio State University, Columbus, Ohio. He conducted post-doctoral training in the laboratory of Dr. John H. Kersey, Dept. of Laboratory Medicine/Pathology at the University of Minnesota. He joined the Masonic Cancer Center in 1984 where he conducts research on the development of new recombinant biological anti-cancer agents.

Dr. Philip Werthman, M.D., MMH

Chairman, Science Advisory Board

Dr. Philip Werthman, M.D., MMH is director of the Center for Male Reproductive Medicine, and former assistant clinical professor of urology at the University of Southern California School of Medicine. Dr. Werthman received his medical degree from Hahnemann University School of Medicine in Philadelphia, graduating valedictorian. Dr. Werthman completed his residency and fellowship in urology at the University of California, Los Angeles (UCLA). He conducted award-winning early research in the field of gene therapy for urologic cancers and innovated a number of microsurgical procedures used today. Dr. Werthman founded Merkava Holdings, a venture capital and advisory company focused on helping grow early stage platform life sciences technologies with expertise in biopharma and medical devices. He currently serves as chairman of the boards of Rithem Life Sciences, LLC and Proxamama Inc. and is a board member or strategic advisor to multiple companies.

Gregory Berk, M.D.

Gregory Berk, M.D.

President of Research & Development, Chief Medical Officer

Dr. Berk brings over 30 years of experience and expertise in oncology drug development across medicine, industry and academia. Prior to joining GT Biopharma, Dr. Berk was Chief Medical Officer of Celularity, where he was responsible for the company's oncology, infectious and degenerative disease programs. Previously, he served as Chief Medical Officer of Verastem; President, Chief Medical Officer, and Board Member of Sideris Pharmaceuticals; Chief Medical Officer of BIND Therapeutics, and Chief Medical Officer of Intellikine, which was acquired by Takeda/Millennium. Prior to his roles as Chief Medical Officer, Dr. Berk was Senior Vice President of Global Clinical Development at Abraxis BioScience, where he was responsible for the Company's overall clinical strategy, including efforts to expand the indications for its lead clinical program, Abraxane®, as well as oversee the clinical development of its clinical pipeline. Dr. Berk also served on the integration leadership team during the Celgene, $3.7 Billion acquisition of Abraxis in 2010.

Dr. Berk obtained his medical degree from Case Western Reserve University and completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Medical College of Cornell University and New York Presbyterian Hospital, where he also served as a faculty member from 1989-2004. During this time, Dr. Berk served as an investigator on several industry-sponsored and cooperative group oncology clinical trials, including the pivotal trials for Gleevec® and Avastin®.